Validation of electronic data on chemotherapy and hormone therapy use in HMOs

Medical Care

Volumn 51, Issue 10, 2013, Pages

  Ritzwoller, Debra P ^a   Carroll, Nikki ^a   Delate, Thomas ^a   O'Keeffe Rossetti, Maureen ^b   Fishman, Paul A ^c   Loggers, Elizabeth T ^c   Aiello Bowles, Erin J ^c   Elston Lafata, Jennifer ^d,e   Hornbrook, Mark C ^b  

^a KAISER PERMANENTE   (United States)

^b CENTER FOR HEALTH RESEARCH   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Cancer; chemotherapy; utilization

Indexed keywords

ANTINEOPLASTIC AGENT;

ACCURACY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER RESEARCH; COLORECTAL CANCER; DATA BASE; DRUG RESISTANCE; ELECTRONIC MEDICAL RECORD; HEALTH MAINTENANCE ORGANIZATION; HUMAN; LUNG CANCER; PHARMACY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COHORT STUDIES; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; DRUG THERAPY; ELECTRONIC HEALTH RECORDS; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HORMONES; HUMANS; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MALE; MEDICAL RECORD LINKAGE; MEDICARE; MIDDLE AGED; NEOPLASMS; PROSTATIC NEOPLASMS; REGISTRIES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84884814525     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31824def85     Document Type: Article

References (29)

1. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEERMedicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 suppl): IV-3-18.
2. Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002;20:3999-4005.
3. Schrag D, Cramer LD, Bach PB, et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93:850-857.
4. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 suppl):IV-55-61.
5. Lamont EB, Lauderdale DS, Schilsky RL, et al. Construct validity of medicare chemotherapy claims: the case of 5FU. Med Care. 2002;40: 201-211.
6. Lamont EB, Herndon JE, Weeks JC, et al. Criterion validity of Medicare chemotherapy claims in cancer and leukemia group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005;97:1080-1083.
7. Wagner EH, Greene SM, Hart G, et al. Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr. 2005;35:3-11.
8. Vogt TM, Wagner EW. Health Care Systems as Research Platforms: The Cancer Research Network. Bethesda, MD: Oxford University Press; 2005.
9. National Cancer Institute. The HMO cancer research network: capacity, collaboration, and inestigation. Washington, D.C.: U.S. Department of Health and Human Services, National Institutes of Health; 2010.
10. Hornbrook MC, Hart G, Ellis JL, et al. Building a virtual cancer researc.organization. J Natl Cancer Inst Monogr. 2005;35:12-25.
11. Go AS, Magid DJ, Wells B, et al. The Cardiovascular Research Network: a new paradigm for cardiovascular quality and outcomes research. Circ Cardiovasc Qual Outcomes. 2008;1:138-147.
12. Lash TL, Fox MP, Buist DS, et al. Mammography surveillance and mortality in older breast cancer survivors. J Clin Oncol. 2007;25:3001-3006.
13. Haque R, Quinn VP, Habel LA, et al. Correlates of screening sigmoidoscopy use among men in a large nonprofit health plan. Cancer. 2007;110:275-281.
14. Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26:549-555.
15. Haque R, Achacoso NS, Fletcher SW, et al. Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care. 2010;16:351-360.
16. Aiello EJ, Buist DS, Wagner EH, et al. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat. 2008;107:397-403.
17. Feigelson H, Rahm AK, Funk K, et al. OS2-11: validation of KRAS mutation testing across five certified laboratories. Clin Med Res. 2011;9:141.
18. Field TS, Bosco JL, Prout MN, et al. Age, comorbidity, and breast cancer severity: impact on receipt of definitive local therapy and rate of recurrence among older women with early-stage breast cancer. J Am Coll Surg. 2011;213:757-765.
19. Haque R, Yood MU, Geiger AM, et al. Long-term safety of radiotherapy and breast cancer laterality in older survivors. Cancer Epidemiol Biomarkers Prev. 2011;20:2120-2126.
20. North American Association of Central Cancer Registries. NAACCR strategic management plan. Available at: http://www.naaccr.org/Home. aspx. Accessed August 26, 2011.
21. Li EC, DeMartino J. Preliminary report: the development of the NCCN comparative therapeutic index as a clinical evaluative process for existing data in oncology. J Natl Compr Canc Netw. 2010;8(suppl 5): S1-S9.
22. National Cancer Institute, Cancer Control and Population Sciences. Health services and economics: procedure codes for SEER-Medicare analyses. Available at: http://healthservices.cancer.gov/seermedicare/considerations/procedure- codes.html. Accessed August 26, 2011.
23. National Cancer Institute. NCI drug dictionary. Available at: http://www.cancer.gov/drugdictionary. Accessed August, 26 2011.
24. Aiello Bowles EJ, Tuzzio L, Ritzwoller DP, et al. Accuracy and complexities of using automated clinical data for capturing chemotherapy administrations: implications for future research. Med Care. 2009;47:1091-1097.
25. Earle CC, Nattinger AB, Potosky AL, et al. Identifying cancer relapse using SEER-Medicare data. Med Care. 2002;40(8 suppl):IV-75-81.
26. Tannock IF, de WR, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
27. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
28. National Cancer Institute. Prostate cancer treatment (PDQs). Available at: http://www.cancer.gov/cancertopics/pdq/treatment/prostate/Health Professional/page4. Accessed August 26, 2011.
29. Du XL, Key CR, Dickie L, et al. External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care. 2006;44:124-131.